Sonoma Pharmaceuticals Inc (SNOA)

Panoramica Notizia Cronologia dei prezzi Financials Perché SNOA Giù? Forum Previsione Frazionamento azionario

Precedente Chiudi:

Volume 24 ore:

Relative Volume:

Capitalizzazione di mercato:

Utile/perdita netta:

Rapporto P/E:

Flusso di cassa netto:

1 W Prestazione:

1M Prestazione:

6M Prestazione:

1 anno Prestazione:

Intervallo 1D:

Intervallo di 1 settimana:

Portata 52W:

Sonoma Pharmaceuticals Inc Stock (SNOA) Company Profile

Sonoma Pharmaceuticals Inc

Healthcare (1104)

800-759-9305

5445 CONESTOGA COURT, SUITE 150, BOULDER, CA

Prossima data di guadagno

Ultimi documenti SEC

SNOA's Discussions on Twitter

Compare SNOA vs TAK, HLN, TEVA, ZTS, UTHR

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
SNOA Sonoma Pharmaceuticals Inc	1.15	3.99M	17.72M	-3.37M	-3.72M	-2.038
TAK Takeda Pharmaceutical Co Adr	15.63	49.39B	29.91B	1.30B	3.49B	0.4056
HLN Haleon Plc Adr	8.96	39.55B	14.54B	2.22B	2.58B	0.4871
TEVA Teva Pharmaceutical Industries Ltd Adr	31.48	36.66B	17.53B	1.58B	444.18M	1.3457
ZTS Zoetis Inc	78.71	33.00B	9.51B	2.64B	2.14B	6.0361
UTHR United Therapeutics Corp	536.59	22.78B	3.17B	1.29B	1.01B	27.09

Sonoma Pharmaceuticals Inc Borsa (SNOA) Ultime notizie

Sonoma Pharmaceuticals Inc Azioni (SNOA) Dati Finanziari

Sonoma Pharmaceuticals Inc (SNOA)

Sonoma Pharmaceuticals Inc Stock (SNOA) Company Profile

Compare SNOA vs TAK, HLN, TEVA, ZTS, UTHR

Sonoma Pharmaceuticals Inc Borsa (SNOA) Ultime notizie

Sonoma Pharmaceuticals Inc (SNOA) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey

Sonoma Pharmaceuticals Files 8-K for $3.6 Million Common Stock Offering – Nasdaq: SNOA, June 2026 - Minichart

According to a recent filing submitted to the U.S. Securities and Exchange Commission (SEC), Sonoma Pharmaceuticals, Inc. has raised the maximum total offering price of its common stock issuance to $3.64 million. - Bitget

Sonoma Pharmaceuticals increases at-the-market offering to $3.64 million - Investing.com UK

Sonoma Pharmaceuticals increases at-the-market offering to $3.64 million By Investing.com - Investing.com Nigeria

Sonoma Pharmaceuticals Expands At-the-Market Equity Offering Capacity - TipRanks

Sonoma Pharmaceuticals Inc - TradingKey

Sonoma Pharmaceuticals boosts shelf offering capacity to $3.64M after prior $574.6K sales - TradingView

[8-K] Sonoma Pharmaceuticals, Inc. Reports Material Event - Stock Titan

Sonoma Pharmaceuticals Inc (SNOA) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey

Sonoma Pharmaceuticals Inc (SNOA) Valuation: PE, PB & Fair Value Analysis - TradingKey

Sonoma Pharmaceuticals Inc (SNOA) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey

Sonoma Pharmaceuticals Inc (SNOA) Institutional Confidence - TradingKey

Sonoma Pharmaceuticals Inc (SNOA) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey

Sonoma Pharmaceuticals Inc (SNOA) Financial Health: Profitability & Balance Sheet Analysis - TradingKey

Sonoma Pharmaceuticals Q4 revenue rises 48% on US growth - TradingView

Sonoma Pharmaceuticals Reports Fiscal Year and Fourth Quarter 2026 Financial Results - ACCESS Newswire

BRIEF-Sonoma Pharmaceuticals Q4 Net Income USD -600 Thousand - TradingView

Sonoma Pharmaceuticals (NASDAQ: SNOA) outlines global HOCl strategy and risks - Stock Titan

SNOA Q1 2026 Earnings: EPS Misses Estimates Amid Operational and Revenue Disclosures - newsline.com

SNOA Should I Buy - Intellectia AI

Sonoma Pharmaceuticals Q1 2026 Earnings: EPS Miss Triggers Sharp SelloffCFO Commentary Report - newsline.com

Sonoma Pharmaceuticals Inc. (SNOA) Q1 2026 Earnings: EPS Falls Short of Estimates, Stock Unchanged - newsline.com

Sonoma Pharmaceuticals (SNOA) Edges Higher, Testing Resistance at $1.13Channel Breakout - The Legal Advocate

SNOA Q1 2026 Earnings: EPS Misses Estimates as Revenue Remains UnreportedEnergy Earnings Report - newsline.com

Sonoma Pharmaceuticals Inc. (SNOA) Q1 2026 Earnings: EPS Slightly Misses Estimates Amid Thin Revenue DisclosuresOne-Time Gain Impact - newsline.com

Sonoma Pharmaceuticals (SNOA) Edges Higher, Testing Key Resistance at $1.13Volatility Smirk - Newser

SNOA SEC FilingsSonoma Pharmaceu 10-K, 10-Q, 8-K Forms - Stock Titan

Sonoma Pharmaceuticals (SNOA) Slips -3.56%, Testing $1.08 Support 2026-05-15Fast Rising Stocks - Newser

Sonoma Pharmaceuticals (SNOA) Q1 2026 Earnings Miss by Significant: Key TakeawaysRevenue Guidance Update - Newser

SNOA Director Jacoby Vanessa Stock Option Filing, May 14, 2026 - Meyka

Sonoma Pharmaceuticals (SNOA) outlines plan to reincorporate from Delaware to Nevada - Stock Titan

Sonoma Pharmaceuticals Completes Equity Offering to Raise Capital - The Globe and Mail

Sonoma Pharmaceuticals Prices $1.35 Unit Offering, Nets ~$3.5M Under Underwriting With Dawson James - TradingView

Sonoma Pharmaceuticals (NASDAQ: SNOA) closes $4M stock and warrant sale - Stock Titan

SNOA Sonoma Pharmaceuticals reports narrow Q1 2026 EPS miss as shares rise 1.92 percent on mild positive investor sentiment.Cost Advantage - Newser

SNOA Director Jacoby Vanessa Stock Option Filing, April 28, 2026 - Meyka

Sonoma Pharmaceuticals registers HOCl facial spray under U.S. cosmetics law - MSN

What's Going On With Sonoma Pharma Stock Monday? - Benzinga

2.96M-unit offering priced at $1.35 — Sonoma Pharmaceuticals (NASDAQ: SNOA) - Stock Titan

SNOA Drops As Sonoma Pharmaceuticals Launches Dilutive Offering - StocksToTrade

Sonoma Pharmaceuticals (SNOA) Secures $4M in Public Offering - GuruFocus

Sonoma Pharmaceuticals prices $4M stock offering at $1.35 per share - Investing.com

Sonoma Pharmaceuticals Announces Pricing of $4 Million Public Offering - ACCESS Newswire

[EFFECT] Sonoma Pharmaceuticals, Inc. SEC Filing - Stock Titan

Sonoma Pharmaceuticals (NASDAQ: SNOA) files S-1 for $5M unit and warrant sale - Stock Titan

SNOA (Sonoma Pharmaceuticals Inc.) Q1 2026 revenue growth drives 2.75 percent share gain despite narrow EPS miss.ROE - UBND thành phố Hải Phòng

SNOA Sonoma Pharmaceuticals shares jump 15 percent on 12 percent Q1 2026 revenue growth despite minor EPS miss.Crowd Entry Points - newser.com

According to the latest filing from the U.S. Securities and Exchange Commission (SEC), Sonoma Pharmaceuticals, Inc. announced the launch of a public offering, aiming to raise a total of $5 million through the issuance of units. - Exchange Bitget

Sonoma Pharmaceuticals | S-1: General form for registration of securities under the Securities Act of 1933 - Moomoo

Sonoma Pharmaceuticals (NASDAQ: SNOA) plans $5M stock and warrant sale - Stock Titan

Sonoma Pharmaceuticals Inc Azioni (SNOA) Dati Finanziari

Reddito

Reddito netto

Flusso di cassa

EPS

Simile a SNOA